Stockreport

Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer

ADURO BIOTECH  (ADRO) 
Last aduro biotech earnings: 3/9 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.aduro.com
PDF BERKELEY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targ [Read more]